Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction.
about
Plunder and stowaways: incorporation of cellular proteins by enveloped virusesBiomedical applications of glycosylphosphatidylinositol-anchored proteinsThe Paramyxoviruses Simian Virus 5 and Mumps Virus Recruit Host Cell CD46 To Evade Complement-Mediated NeutralizationComplement and its role in protection and pathogenesis of flavivirus infectionsThe good and evil of complement activation in HIV-1 infectionCellular compartments of human immunodeficiency virus type 1 replication in vivo: determination by presence of virion-associated host proteins and impact of opportunistic infection.Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts.Complement Evasion Strategies of Viruses: An Overview.The resistance of retroviral vectors produced from human cells to serum inactivation in vivo and in vitro is primate species dependent.Detection of antibody-dependent complement-mediated inactivation of both autologous and heterologous virus in primary human immunodeficiency virus type 1 infection.Differential incorporation of CD45, CD80 (B7-1), CD86 (B7-2), and major histocompatibility complex class I and II molecules into human immunodeficiency virus type 1 virions and microvesicles: implications for viral pathogenesis and immune regulationV1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144.A novel trifunctional IgG-like bispecific antibody to inhibit HIV-1 infection and enhance lysis of HIV by targeting activation of complementCellular proteins associated with the interior and exterior of vesicular stomatitis virus virionsProtein analysis of purified respiratory syncytial virus particles reveals an important role for heat shock protein 90 in virus particle assembly.Poxvirus complement control proteins are expressed on the cell surface through an intermolecular disulfide bridge with the viral A56 protein.Provirus activation plus CD59 blockage triggers antibody-dependent complement-mediated lysis of latently HIV-1-infected cells.Human CD59 incorporation into porcine endogenous retrovirus particles: implications for the use of transgenic pigs for xenotransplantationComplement and HIV-I infection/HIV-associated neurocognitive disorders.A high-affinity inhibitor of human CD59 enhances complement-mediated virolysis of HIV-1: implications for treatment of HIV-1/AIDSPotential roles of cellular proteins in HIV-1.A novel factor I activity in Nipah virus inhibits human complement pathways through cleavage of C3bXenotransplantation and pig endogenous retroviruses.Induction of ebolavirus cross-species immunity using retrovirus-like particles bearing the Ebola virus glycoprotein lacking the mucin-like domain.Blockage of CD59 Function Restores Activities of Neutralizing and Nonneutralizing Antibodies in Triggering Antibody-Dependent Complement-Mediated Lysis of HIV-1 Virions and Provirus-Activated Latently Infected Cells.Evasion and interactions of the humoral innate immune response in pathogen invasion, autoimmune disease, and cancerPurification of infectious human herpesvirus 6A virions and association of host cell proteins.Membrane cholesterol: a crucial molecule affecting interactions of microbial pathogens with mammalian cellsLipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses.Characterization and role of lentivirus-associated host proteins.Effect of complement on HIV-2 plasma antiviral activity is intratype specific and potent.Humoral immunity to HIV-1: neutralization and beyond.Application of proteomics technology for analyzing the interactions between host cells and intracellular infectious agents.Diverse viral glycoproteins as well as CD4 co-package into the same human immunodeficiency virus (HIV-1) particles.Caveolae provide a specialized membrane environment for respiratory syncytial virus assembly.Reduced sensitivity to human serum inactivation of enveloped viruses produced by pig cells transgenic for human CD55 or deficient for the galactosyl-alpha(1-3) galactosyl epitope.Immune Protection of Retroviral Vectors Upon Molecular Painting with the Complement Regulatory Protein CD59.Major chimpanzee-specific structural changes in sperm development-associated genes.How novel structures inform understanding of complement function.Comprehensive Cross-Clade Characterization of Antibody-Mediated Recognition, Complement-Mediated Lysis, and Cell-Mediated Cytotoxicity of HIV-1 Envelope-Specific Antibodies toward Eradication of the HIV-1 Reservoir.
P2860
Q24524170-F7688505-ACD6-4302-AD6D-9DC3A0B9EA99Q27468625-32BD2C57-9A68-412D-8FE7-4B661BB6382CQ27488882-950DC122-6E3D-44D1-844E-04F44DC4DD82Q27490236-ED98A10C-B1A6-408F-80E7-8AF6D38A0BDBQ28275986-89C10423-9EFF-4E58-9729-BAC088A17906Q33794467-7C8EF926-57C0-4101-8B4B-04EF707AB5DCQ33801455-B340AD75-3829-4D9E-A035-09E01B5A6401Q33804431-2C5F24C7-A445-43F8-9EF4-462A2234DFC7Q33817487-AB98BCC1-9EDF-4E25-BF73-4B04BF542ABBQ33834852-839F2DA8-EB13-4D96-8E80-073AEF68B226Q33842620-337082B2-A132-4499-A5F0-8DD9EEFA9249Q33874253-231D4365-FD67-43C9-8FF8-A5F4DD5D121AQ33997980-7D6D01BF-1E14-464D-8208-08A69485EF89Q34020589-E663EFB3-BC36-4D98-B44E-87EB081BAB38Q34122163-2AEFCED7-FCBE-44DC-831B-010ACBF63703Q34190609-F702646A-B5A0-48FF-AA81-01FD346AFC14Q34218827-EFDC3021-1D1A-4684-8C92-BBDC84B90306Q34331007-20654CA1-ED11-4E86-890F-394120F256AEQ34610122-20CDF465-6C22-4D4A-B584-8F585FB72535Q34749137-AEADF906-2462-4380-BB70-019C1153A5EBQ34985857-1AA5669B-0A5F-4F7E-9D5A-80DB2931C26BQ34991123-B8454726-0E8E-41A5-B672-FAAA54375C70Q35204263-1A644FE2-8522-44E7-984E-808E12871AA8Q35772032-2BDF5443-42E7-42FF-874E-1E855AE13281Q35973601-1F73017F-C587-4C1C-AD72-3BF9F766A6AAQ36090335-F4FD6EF5-A665-44C5-83A0-B22C83533A07Q36310683-34B14775-88A5-45A1-BB31-6E2A383A2A47Q36318116-2CD9497D-CC8B-47A3-ABB2-528B844999A9Q36370336-8A44D324-83DD-4B36-A832-7382F9BF9086Q36412305-DB66F2F9-015D-4C13-A47B-8B9752E1D9ADQ36506821-8E74C1D8-96D8-4B2A-8CDA-D2D9C88428E7Q36863847-A76F0EB6-D4D0-4A26-BCBC-C085147AF110Q37093742-7D506FC0-270A-4FB8-A452-C04AFF6BE6A7Q37701191-D4107786-5E57-4C66-8F62-5D2C3C39911CQ37711566-FCF653AB-4D90-4111-A95B-2B34DE26F5D5Q38341233-FEBB31E6-4769-417C-A25C-95765ECECC98Q38408016-F7F2FC3C-50AB-4CAA-B5F8-88EB078DE368Q38502707-FB53F1CB-2C42-4D83-9E44-A2E1A6C89E84Q38624669-147FD5F2-6327-4568-BCA4-62AC8406619AQ38673539-D2AD10CB-E8F8-4E2D-9473-146BD60A5FE8
P2860
Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh-hant
name
Human immunodeficiency virus t ...... mplement-mediated destruction.
@en
Human immunodeficiency virus t ...... mplement-mediated destruction.
@nl
type
label
Human immunodeficiency virus t ...... mplement-mediated destruction.
@en
Human immunodeficiency virus t ...... mplement-mediated destruction.
@nl
prefLabel
Human immunodeficiency virus t ...... mplement-mediated destruction.
@en
Human immunodeficiency virus t ...... mplement-mediated destruction.
@nl
P2093
P1476
Human immunodeficiency virus t ...... mplement-mediated destruction.
@en
P2093
Atkinson JP
Hedayati T
Holguin MH
Saifuddin M
P304
P356
10.1099/0022-1317-78-8-1907
P407
P478
78 ( Pt 8)
P577
1997-08-01T00:00:00Z